Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker COGT
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | James E. Flynn | 5.01M | 2.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Deerfield Partners, L.P. | 5.01M | 2.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Deerfield Management Company, L.P. | 5.01M | 2.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Deerfield Mgmt, L.P. | 5.01M | 2.9% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G | COGT Cogent Biosciences, Inc. | Vanguard Capital Management | 8.69M | 5.1% | SCHEDULE 13G ↗ |
| Jul 27, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | BlackRock, Inc. | 13.59M | 8.0% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | James E. Flynn | 9.04M | 5.3% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Deerfield Partners, L.P. | 9.04M | 5.3% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Deerfield Management Company, L.P. | 9.04M | 5.3% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Deerfield Mgmt, L.P. | 9.04M | 5.3% | SCHEDULE 13G/A ↗ |
| Mar 31, 2026 | SCHEDULE 13D/A (amended) | COGT Cogent Biosciences, Inc. | Fairmount Healthcare Fund II GP LLC | 15.36M | 8.6% | SCHEDULE 13D/A ↗ |
| Mar 31, 2026 | SCHEDULE 13D/A (amended) | COGT Cogent Biosciences, Inc. | Fairmount Funds Management LLC | 15.36M | 8.6% | SCHEDULE 13D/A ↗ |
| Mar 26, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Yue Tang | 6.17M | 4.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Kynam Capital Management GP, LLC | 6.17M | 4.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Kynam Capital Management, LP | 6.17M | 4.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Michael Kramarz | 2.80M | 1.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Robert Egen Atkinson | 2.80M | 1.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Commodore Capital Master LP | 2.80M | 1.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Commodore Capital LP | 2.80M | 1.8% | SCHEDULE 13G/A ↗ |
| Jan 30, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | The Vanguard Group | 11.51M | 7.5% | SCHEDULE 13G/A ↗ |
| Jan 22, 2026 | SCHEDULE 13D/A (amended) | COGT Cogent Biosciences, Inc. | Fairmount Healthcare Fund II GP LLC | 16.26M | 9.9% | SCHEDULE 13D/A ↗ |
| Jan 22, 2026 | SCHEDULE 13D/A (amended) | COGT Cogent Biosciences, Inc. | Fairmount Funds Management LLC | 16.26M | 9.9% | SCHEDULE 13D/A ↗ |
| Jan 21, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | BlackRock, Inc. | 11.37M | 6.5% | SCHEDULE 13G/A ↗ |
| Jan 21, 2026 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | BlackRock, Inc. | 11.37M | 6.5% | SCHEDULE 13G/A ↗ |
| Nov 17, 2025 | SCHEDULE 13D/A (amended) | COGT Cogent Biosciences, Inc. | Fairmount Healthcare Fund II GP LLC | 15.88M | 9.9% | SCHEDULE 13D/A ↗ |
| Nov 17, 2025 | SCHEDULE 13D/A (amended) | COGT Cogent Biosciences, Inc. | Fairmount Funds Management LLC | 15.88M | 9.9% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Yue Tang | 7.89M | 5.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Kynam Capital Management GP, LLC | 7.89M | 5.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Kynam Capital Management, LP | 7.89M | 5.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Michael Kramarz | 10.21M | 7.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Robert Egen Atkinson | 10.21M | 7.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Commodore Capital Master LP | 10.21M | 7.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Commodore Capital LP | 10.21M | 7.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Chen Yu | 6.80M | 4.8% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | TCG Crossover Fund I, L.P. | 6.80M | 4.8% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | TCG Crossover GP I, LLC | 6.80M | 4.8% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Paradigm BioCapital International Fund Ltd. | 2.79M | 2.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Senai Asefaw, M.D. | 3.16M | 2.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Paradigm BioCapital Advisors GP LLC | 3.16M | 2.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Paradigm BioCapital Advisors LP | 3.16M | 2.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Steven A. Cohen | 5.75M | 4.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Point72 Capital Advisors, Inc. | 5.75M | 4.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Point72 Asset Management, L.P. | 5.75M | 4.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G | COGT Cogent Biosciences, Inc. | Michael Kramarz | 6.41M | 5.5% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G | COGT Cogent Biosciences, Inc. | Robert Egen Atkinson | 6.41M | 5.5% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G | COGT Cogent Biosciences, Inc. | Commodore Capital Master LP | 6.41M | 5.5% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G | COGT Cogent Biosciences, Inc. | Commodore Capital LP | 6.41M | 5.5% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Commodore Capital Master LP | 5.27M | 4.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | COGT Cogent Biosciences, Inc. | Commodore Capital LP | 5.27M | 4.6% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:23 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances